LCC has announced that Dr Gary Tilbrook has been appointed to the Board of the Company as a Chief Scientific Officer.
Gary is an experienced medicinal chemist with an in-depth knowledge of drug discovery and development, built from working within the biotech sector for over 25 years. Gary’s experience covers all practical aspects of the drug discovery process from target and hit identification, through to lead optimisation, candidate selection, process chemistry R&D and technical/intellectual property due diligence support for in/out licensing opportunities. Gary made key contributions relating to the pre-clinical, CMC and early clinical development of the ex-Glaxo Wellcome asset GW502056X, the first ultra-short acting injectable benzodiazepine Remimazolam (Byfavo®), now commercialised worldwide.
Gary’s breadth of expertise is a great fit for LCC’s ongoing mission of improving access to chirally pure chemical space for NCE discovery and development, and we can’t wait to see what he brings to Team LCC.